Abstract
Purpose
In postmenopausal women under L-T4 therapy, which was subsequently accompanied by calcium carbonate (CC) supplementation taken 6–8 h after tablet L-T4, TSH levels were greater than prior to adding CC. Total cholesterolemia [CHOL], fasting glycemia [FG], systolic and diastolic blood pressure [SBP, DBP] were also greater than baseline. Our aim was to explore the effects of either liquid or softgel capsule L-T4, while maintaining CC ingestion 6–8 h, later on TSH levels, CHOL, FG, SBP, and DBP.
Methods
We proposed to 50 hypothyroid postmenopausal women under tablet L-T4 therapy, to switch to either liquid or softgel capsule L-T4 at the same daily dose while maintaining CC ingestion 6–8 h later. Sixteen women accepted [group I; liquid (n = 9), capsule (n = 7)], while 34 continued tablet L-T4 [group II, (n = 34)].
Results
After 3 months, in group I, TSH decreased significantly (1.23 ± 0.49 vs. 1.80 ± 0.37 mU/L, P < 0.01), as did FG (80.7 ± 7.9 vs. 83.4 ± 6.3 mg/dL, P < 0.05); CHOL, SBP, and DBP decreased, though insignificantly. In contrast, in group II, TSH, FG, CHOL, SBP increased insignificantly, and DBP increased borderline significantly (69.7 ± 9 vs. 66.3 ± 6.5, P < 0.10). Compared to baseline (before adding CC), in group I, TSH was significantly lower (P < 0.01) and the other indices similar; in group II, TSH, FG, and SBP were significantly higher (P < 0.05), DBP borderline significantly higher (P < 0.10) and CHOL insignificantly higher. Performance of liquid L-T4 and capsule L-T4 was similar.
Conclusion
Delaying CC ingestion even by 6–8 h after taking tablet L-T4 is not entirely satisfactory, unlike liquid or softgel L-T4.
Similar content being viewed by others
Change history
28 June 2019
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
References
C.R. Schneyer, Calcium carbonate and reduction of levothyroxine efficacy [letter]. JAMA 279, 750 (1998)
N. Singh, P.N. Singh, J.M. Hershman, Effect of calcium carbonate on the absorption of levothyroxine. JAMA 283, 2822–2825 (2000)
I. Zamfirescu, H.E. Carlson, Absorption of levothyroxine when coadministered with various calcium formulations. Thyroid 21, 483–486 (2011)
S. Benvenga, F. Di Bari, R. Vita, Undertreated hypothyroidism due to calcium or iron supplementation corrected by oral liquid levothyroxine. Endocrine 56, 138–145 (2017)
P. Colucci, C. Seng Yue, M. Ducharme, S. Benvenga, A review of the pharmacokinetics of levothyroxine for the treatment of hypothyroidism. Eur. Endocrinol. 9, 40–47 (2013)
S. Benvenga, When thyroid hormone replacement is ineffective? Curr. Opin. Endocrinol. Diabetes Obes. 20, 467–477 (2013)
E. Morini, A. Catalano, A. Lasco, N. Morabito, S. Benvenga, l-thyroxine malabsorption due to calcium carbonate impairs blood pressure, total cholesterolemia, and fasting glycemia. Endocrine (2018). https://doi.org/10.1007/s12020-018-1798-7
J.R. Garber, R.H. Cobin, H. Gharib et al. Clinical practice guidelines for hypothyroidism for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 22, 1200–1235 (2012)
I.L. Klein, S. Danzi, in Werner and Ingbar’s the Thyroid: a Fundamental and Clinical Text, ed. by L.E Bravermann, D.S Cooper (Wolters Kluver, Lippincott, Willimas & Wilkins, Philadelphia, 2013), p. 575–582
B.O. Asvold, L.J. Vatten, T.I. Nilsen, T. Bjøro, The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT Study. Eur. J. Endocrinol. 156, 181–186 (2007)
T.N. Le, F.S. Celi, E.P. Wickham 3rd, Thyrotropin levels are associated with cardiometabolic risk factors in euthyroid adolescents. Thyroid 26, 1441–1449 (2016)
B. Xu, H. Yang, Z. Wang, T. Yang, H. Guo, P. Cheng, W. He, M. Sun, H. Chen, Y. Duan, Elevated thyroid stimulating hormone levels are associated with metabolic syndrome in a Chinese community-based population of euthyroid people aged 40 years and older. J. Biomed. Res. 30, 476–482 (2016)
I.M. Benseñor, A.C. Goulart, C. Molina Mdel, É.J. de Miranda, I.S. Santos, P.A. Lotufo, Thyrotropin levels, insulin resistance, and metabolic syndrome: a cross-sectional analysis in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Metab. Syndr. Relat. Disord. 13, 362–369 (2015)
A. Javed, P.B. Balagopal, A. Vella, P.R. Fischer, F. Piccinini, C. Dalla Man, C. Cobelli, P.D. Giesler, J.M. Laugen, S. Kumar, Association between thyrotropin levels and insulin sensitivity in euthyroid obese adolescents. Thyroid 25, 478–484 (2015)
J. Alam, M.N.-E.-T.M. Mukti, M. Hoque, I. Ali, M. Kamal, S.C. Mallik, S. Choudhury, Cross sectional evaluation of thyroid hormone levels in non-diabetic and diabetic patients in Bangladeshi population. Asian J. Biol. Sci. 6, 228–233 (2013)
H.T. Park, G.J. Cho, K.H. Ahn, J.H. Shin, S.C. Hong, T. Kim, J.Y. Hur, Y.T. Kim, K.W. Lee, S.H. Kim, Thyroid stimulating hormone is associated with metabolic syndrome in euthyroid postmenopausal women. Maturitas 62, 301–305 (2009)
A. Giandalia, G.T. Russo, E.L. Romeo, A. Alibrandi, P. Villari, A.A. Mirto, G. Armentano, S. Benvenga, D. Cucinotta, Influence of high-normal serum TSH levels on major cardiovascular risk factors and Visceral Adiposity Index in euthyroid type 2 diabetic subjects. Endocrine 47, 152–160 (2014)
J.E. Jun, S.M. Jin, J.H. Jee, J.C. Bae, K.Y. Hur, M.K. Lee, S.W. Kim, J.H. Kim, TSH increment and the risk of incident type 2 diabetes mellitus in euthyroid subjects. Endocrine 55, 944–953 (2017)
V. Velkoska Nakova, B. Krstevska, M. Bosevski, Ch Dimitrovski, V. Serafimoski, Dyslipidaemia and hypertension in patients with subclinical hypothyroidism. Prilozi 30, 93–102 (2009)
Y. Zhang, P. Lu, L. Zhang, X. Xiao, Association between lipids profile and thyroid parameters in euthyroid diabetic subjects: a cross-sectional study. BMC Endocr. Disord. 15, 12 (2015). https://doi.org/10.1186/s12902-015-0008-3
V.L. Langén, T.J. Niiranen, P. Puukka, J. Sundvall, A.M. Jula, V.L. Langén, T.J. Niiranen, P. Puukka, J. Sundvall, A.M. Jula, Association between thyroid-stimulating hormone and blood pressure in adults: an 11-year longitudinal study. Clin. Endocrinol. 84, 741–747 (2016)
T. Ittermann, D. Tiller, C. Meisinger, C. Agger, M. Nauck, R. Rettig, A. Hofman, T. Jørgensen, A. Linneberg, J.C. Witteman, O.H. Franco, K.H. Greiser, K. Werdan, A. Döring, A. Kluttig, B.H. Stricker, H. Völzke, High serum thyrotropin levels are associated with current but not with incident hypertension. Thyroid 23, 955–963 (2013)
Y. Duan, W. Peng, X. Wang, W. Tang, X. Liu, S. Xu, X. Mao, S. Feng, Y. Feng, Y. Qin, K. Xu, C. Liu, C. Liu, Community-based study of the association of subclinical thyroid dysfunction with blood pressure. Endocrine 35, 136–142 (2009)
R. Luboshitzky, A. Aviv, P. Herer, L. Lavie, Risk factors for cardiovascular disease in women with subclinical hypothyroidism. Thyroid 12, 421–425 (2002)
D. Liu, F. Jiang, Z. Shan, B. Wang, J. Wang, Y. Lai, Y. Chen, M. Li, H. Liu, C. Li, H. Xue, N. Li, J. Yu, L. Shi, X. Bai, X. Hou, L. Zhu, L. Lu, S. Wang, Q. Xing, W. Teng, A cross-sectional survey of relationship between serum TSH level and blood pressure. J. Hum. Hypertens. 24, 134–138 (2010)
W.X. Jian, J. Jin, L. Qin, W.J. Fang, X.R. Chen, H.B. Chen, Q. Su, H.L. Xing, Relationship between thyroid-stimulating hormone and blood pressure in the middle-aged and elderly population. Singap. Med. J. 54, 401–405 (2013)
L. Petrosyan, Relationship between high normal TSH levels and metabolic syndrome components in type 2 diabetic subjects with euthyroidism. J. Clin. Transl. Endocrinol. 2, 110–113 (2015)
B.O. Asvold, T. Bjøro, T.I. Nilsen, L.J. Vatten, Association between blood pressure and serum thyroid-stimulating hormone concentration within the reference range: a population-based study. J. Clin. Endocrinol. Metab. 92, 841–845 (2007)
A. Iqbal, Y. Figenschau, R. Jorde, Blood pressure in relation to serum thyrotropin: the Tromsø study. J. Hum. Hypertens. 20, 932–936 (2006)
O. Gumieniak, T.S. Perlstein, P.N. Hopkins, N.J. Brown, L.J. Murphey, X. Jeunemaitre, N.K. Hollenberg, G.H. Williams, Thyroid function and blood pressure homeostasis in euthyroid subjects. J. Clin. Endocrinol. Metab. 89, 3455–3461 (2004)
K. Saltiki, P. Voidonikola, K. Stamatelopoulos, E. Mantzou, C. Papamichael, M. Alevizaki, Association of thyroid function with arterial pressure in normotensive and hypertensive euthyroid individuals: a cross-sectional study. Thyroid Res. 1(1), 3 (2008)
A. Tsuda, M. Inaba, M. Ichii, A. Ochi, Y. Ohno, S. Nakatani, S. Yamada, K. Mori, H. Tahara, E. Ishimura, Relationship between serum TSH levels and intrarenal hemodynamic parameters in euthyroid subjects. Eur. J. Endocrinol. 169, 45–50 (2013)
M. Laclaustra, Y. Hurtado-Roca, M. Sendin, M. Leon, M. Ledesma, E. Andres, A. Fernandez-Ortiz, E. Guallar, J.M. Ordovas, J.A. Casasnovas, Lower-normal TSH is associated with better metabolic risk factors: a cross-sectional study on Spanish men. Nutr. Metab. Cardiovasc. Dis. 25, 1095–1103 (2015)
C. Virili, A. Antonelli, M.G. Santaguida, S. Benvenga, M. Centanni, Gastrointestinal malabsorption of thyroxine. Endocr. Rev. 40(1), 118–136 (2019)
P.M. Mannucci, A. Nobili, L. Pasina, REPOSI Collaborators (REPOSI is the acronym of REgistro POliterapie SIMI, Società Italiana di Medicina Interna). Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register. Intern. Emerg. Med. 13(8), 1191–1200 (2018)
R. Vita, G. Saraceno, F. Trimarchi, S. Benvenga, Switching levothyroxine from the tablet to the oral solution formulation corrects the impaired absorption of levothyroxine induced by proton-pump inhibitors. J. Clin. Endocrinol. Metab. 99, 4481–4486 (2014)
C. Virili, L. Giovanella, P. Fallahi, A. Antonelli, M.G. Santaguida, M. Centanni, P. Trimboli, Levothyroxine therapy: changes of TSH levels by switching patients from tablet to liquid formulation. A systematic review and meta-analysis. Front Endocrinol. 9, 10 (2018). https://doi.org/10.3389/fendo.2018.00010
R. Vita, F. Di Bari, S. Benvenga, Oral liquid levothyroxine solves the problem of tablet levothyroxine malabsorption due to concomitant intake of multiple drugs. Expert. Opin. Drug Deliv. 14, 467–472 (2017)
C. Virili, P. Trimboli, F. Romanelli, M. Centanni, Liquid and softgel levothyroxine use in clinical practice: state of the art. Endocrine 54(1), 3–14 (2016)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
S.B. received novel formulations of LT4 from IBSA Institute Biochimique (Lugano, Switzerland) and IBSA s.r.l. (Lodi, Italy) to be given to patients for conducting clinical studies. In addition, S.B. was an invited speaker at symposia organized by IBSA. However, IBSA had no role in any phase of the writing of this manuscript. The remaining authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of our institutional research committee at University Hospital of Messina and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Morini, E., Catalano, A., Lasco, A. et al. In thyroxine-replaced hypothyroid postmenopausal women under simultaneous calcium supplementation, switch to oral liquid or softgel capsule l-thyroxine ensures lower serum TSH levels and favorable effects on blood pressure, total cholesterolemia and glycemia. Endocrine 65, 569–579 (2019). https://doi.org/10.1007/s12020-019-01908-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-019-01908-x